Skip to main content
. Author manuscript; available in PMC: 2013 May 14.
Published in final edited form as: J Neurosci. 2012 Nov 14;32(46):16314–16330. doi: 10.1523/JNEUROSCI.2097-12.2012

Table 2.

Effects of Ca2+ current blockers on action potentials

Apex latency (ms) amplitude (mV) width (ms) Base latency (ms) amplitude (mV) width (ms)
Control (n = 7) 3.2 ± 1.4 93 ± 6 1.8 ± 0.4 (n = 6) 8.4 ± 1.4 111 ± 10 9.2 + 1.4
4-AP 3.0 ± 0.7 54 ± 11 3.8 ± 0.5 6.5 ± 0.7 78 ± 12* 11.6 + 1.5
4-AP + mibefradil 3.5 ± 1.1 39 ± 9** 5.2 ± 0.9* 13.5 ± 2.6* 46 ± 15** 18.5 + 1.8**
Control (n = 8) 4.1 ± 1.2 94 ± 8 1.9 ± 0.4 (n = 8) 9.3 ± 0.9 107 ± 12 8.8 + 1.6
4-AP 3.9 ± 1.5 71 ± 5 3.6 ± 0.3 6.7 ± 1.1 81 ± 9 10.2 + 0.5
4-AP + rSNX 7.0 ± 2.0* 67 ± 10* 6.2 ± 0.3** 3.4 ± 0.4* 68 ± 16** 16 + 1.4*
Control (n = 6) 4.4 ± 1.6 105 ± 13 1.8 ± 0.6 (n = 5) 9.5 ± 1.8 110 ± 12 8.6 + 1.4
4-AP 3.9 ± 1.1 78 ± 12 2.9 ± 0.5 9.9 ± 2.3 86 ± 16 10.4 + 1.6
4-AP + ω-Agatoxin 9.1 ± 2.3* 43 ± 10** 10 ± 1.5** 5.1 ± 0.5* 57 ± 14** 18.9 + 2.2**
Control (n = 7) 3.7 ± 1.3 97 ± 7 2.0 ± 0.3 (n = 7) 8.2 ± 1.3 105 ± 15 7.9 + 1.5
4-AP 3.2 ± 1.1 82 ± 16 3.2 ± 1.4 7.1 ± 1.5 89 ± 16 9.1 + 2.1
4-AP + ω-Conotoxin 7.4 ± 1.3* 78 ± 20 4.1 ± 1.5 11.8 ± 0.5* 85 ± 20 12 + 4.4
Control (n = 8) 4.0 ± 1.6 101 ± 14 1.7 ± 0.5 (n = 9) 7.9 ± 1.8 121 ± 26 10 + 1.3
4-AP 3.9 ± 1.4 89 ± 12 3.4 ± 0.6 7.2 ± 2.1 80 ± 13 13 + 0.8
4-AP + Nimodipine 6.8 ± 0.5* 71 ± 5* 8.1 ± 0.7* 3.1 ± 1.1* 51 ± 7* 19 + 1.7*

4-AP 4-aminopyridine,

*

p < 0.05;

**

p < 0.01 ; n = number of cells.